NCT02778971View on ClinicalTrials.gov

Implications for Management of PET Amyloid Classification Technology

CompletedOBSERVATIONAL
Enrollment

41

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

September 30, 2022

Conditions
Mild Cognitive ImpairmentDementiaAlzheimer's Disease
Interventions
DRUG

[18F]Flutemetamol

amyloid PET imaging with \[18F\]Flutemetamol and subsequent modification of diagnosis and management

Trial Locations (1)

84108-1225

Center for Alzheimer's Care, Imaging & Research, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER

NCT02778971 - Implications for Management of PET Amyloid Classification Technology | Biotech Hunter | Biotech Hunter